logo logo-mobile

  • Home
  • About Us
    • About Us
    • Milestones
    • Contact Us
  • Science and Technology
    • mRNA Research and Development Technology Platform
    • mRNA-DC Vaccines
    • mRNA-LNP Vaccines
  • Research
    • Publications
  • Zhuhai
    • Services
English | 简体中文

logo logo-mobile

En | 中文
  • Home
  • About Us
    • About Us
    • Milestones
    • Contact Us
  • Science and Technology
    • mRNA Research and Development Technology Platform
    • mRNA-DC Vaccines
    • mRNA-LNP Vaccines
  • Research
    • Publications
  • Zhuhai
    • Services
English| 简体中文

Research

—

  • Home
  • Research
  • Publications

About Us

Milestones

Contact Us

  • A highly efficient needle-free-injection delivery system for mRNA-LNP vaccination against SARS-CoV-2
    A highly efficient needle-free-injection delivery system for mRNA-LNP vaccination against SARS-CoV-2
    2024-12-10
    启辰生
    Time:2024-12-10
    Mao S, Li S, Zhang Y, Long L, Peng J, Cao Y, Mao JZ, Qi X, Xin Q, San G, Ding J, Jiang J, Bai X, Wang Q, Xu P, Xia H, Lu L, Xie L, Kong D, Zhu S, Xu W. A highly efficient needle-free-injection deliver
    more
  • Enhanced Human T Lymphocyte Antigen Priming by Cytokine-Matured Dendritic Cells Overexpressing Bcl-2 and IL-12.
    Enhanced Human T Lymphocyte Antigen Priming by Cytokine-Matured Dendritic Cells Overexpressing Bcl-2 and IL-12.
    2024-12-10
    启辰生
    Time:2024-12-10
    Zhang, H., Y. Wang, Q. T. Wang, S. N. Sun, S. Y. Li, H. Shang and Y. W. He (2020). "Enhanced Human T Lymphocyte Antigen Priming by Cytokine-Matured Dendritic Cells Overexpressing Bcl-2 and IL-12." Fro
    more
  • Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study
    Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study
    2024-12-10
    启辰生
    Time:2024-12-10
    Zeng Z, Yang A, Yang J, Zhang S, Xing Z, Wang X, Mei W, Jiang C, Lin J, Wu X, Xue Y, Wu Z, Yu L, Wang D, Chen J, Zheng S, Lin Q, Chen Q, Dong J, Zheng X, Wang J, Huang J, Chen Z, Chen P, Zheng M, Zhou
    more
  • Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients.
    Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients.
    2024-12-10
    启辰生
    Time:2024-12-10
    Wang, Q. T., Y. Nie, S. N. Sun, T. Lin, R. J. Han, J. Jiang, Z. Li, J. Q. Li, Y. P. Xiao, Y. Y. Fan, X. H. Yuan, H. Zhang, B. B. Zhao, M. Zeng, S. Y. Li, H. X. Liao, J. Zhang and Y. W. He (2020). "Tum
    more
  • Targeting Neoantigens in Hepatocellular Carcinoma for Immunotherapy: A Futile Strategy?
    Targeting Neoantigens in Hepatocellular Carcinoma for Immunotherapy: A Futile Strategy?
    2024-11-14
    启辰生
    Time:2024-11-14
    Lu, L., J. Jiang, M. Zhan, H. Zhang, Q. T. Wang, S. N. Sun, X. K. Guo, H. Yin, Y. Wei, J. O. Liu, S. Y. Li, Y. Li and Y. W. He (2021). "Targeting Neoantigens in Hepatocellular Carcinoma for Immunother
    more
  • Clinically approved combination immunotherapy: Current status, limitations, and future perspective
    Clinically approved combination immunotherapy: Current status, limitations, and future perspective
    2024-11-14
    启辰生
    Time:2024-11-14
    Lu L, Zhan M, Li XY, Zhang H, Dauphars DJ, Jiang J, Yin H, Li SY, Luo S, Li Y, He YW. Clinically approved combination immunotherapy: Current status, limitations, and future perspective. Curr Res Immun
    more
  • Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C
    Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C
    2024-11-13
    启辰生
    Time:2024-11-13
    Zhu P, Li SY, Ding J, Fei Z, Sun SN, Zheng ZH, Wei D, Jiang J, Miao JL, Li SZ, Luo X, Zhang K, Wang B, Zhang K, Pu S, Wang QT, Zhang XY, Wen GL, Liu JO, August JT, Bian H, Chen ZN, He YW. Combination
    more
  • Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
    Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
    2024-11-13
    启辰生
    Time:2024-11-13
    Lu, L., H. Zhang, M. Zhan, J. Jiang, H. Yin, D. J. Dauphars, S. Y. Li, Y. Li and Y. W. He (2020). "Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?" Sci
    more
  • Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies.
    Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies.
    2024-11-13
    启辰生
    Time:2024-11-13
    Lu, L., J. Jiang, M. Zhan, H. Zhang, Q. T. Wang, S. N. Sun, X. K. Guo, H. Yin, Y. Wei, S. Y. Li, J. O. Liu, Y. Li and Y. W. He (2021). "Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma
    more
  • Preventing Mortality in COVID-19 Patients: Which Cytokine to Target in a Raging Storm?
    Preventing Mortality in COVID-19 Patients: Which Cytokine to Target in a Raging Storm?
    2024-11-13
    启辰生
    Time:2024-11-13
    Lu, L., H. Zhang, M. Zhan, J. Jiang, H. Yin, D. J. Dauphars, S. Y. Li, Y. Li and Y. W. He (2020). "Preventing Mortality in COVID-19 Patients: Which Cytokine to Target in a Raging Storm?" Front Cell De
    more
    • 1

一 ABOUT US

  • About Us
  • Milestones
  • Contact Us

一 SCIENCE AND TECHNOLOGY

  • mRNA Research and Development Technology Platform
  • mRNA-DC Vaccines
  • mRNA-LNP Vaccines

一 Research

  • Publications

一 Contact us

Contact us

WeChat Official Account

copyright 1993-2026Beijing Tricision Biotechnology CoLtd | NOJingCP2022016228